Abstract
Upper urinary tract transitional cell carcinoma (UTTCC) of the upper urinary tract is rare. The nephroureterectomy with bladder-cuff excision has been the "gold standard" to treat UTTCC. However, a certain cohort of the population will require alternative treatment options due to comorbidities. Percutaneous treatment has become one feasible approach to treat UTTCC. Results have been acceptable when compared to the gold standard therapy, nephroureterectomy with bladder-cuff excision. However, the efficacy of intracavitary Bacillus Calmette-Guérin (BCG) therapy has been conflicting. Randomized trial is necessary to assess the efficacy of intracavitary BCG treatment for UTTCC.
Original language | English (US) |
---|---|
Title of host publication | Smith's Textbook of Endourology |
Subtitle of host publication | 3rd Edition |
Publisher | Wiley-Blackwell |
Pages | 316-325 |
Number of pages | 10 |
Volume | 1 |
ISBN (Print) | 1444335545, 9781444335545 |
DOIs | |
State | Published - Jan 5 2012 |
Externally published | Yes |
Keywords
- BCG
- Bladder-cuff excision
- Endoscopic treatment
- Laser ablation
- Nephroureterectomy
- Percutaneous access
- Percutaneous treatment
- Renal pelvis
- Tumor resection
- Upper urinary tract transitional cell carcinoma
- Ureter
ASJC Scopus subject areas
- General Medicine